Turalio (pexidartinib) / Daiichi Sankyo  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turalio (pexidartinib) / Daiichi Sankyo
PLX3397, NCT04526704 / 2020-000192-20: Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Completed
4
32
Europe, US, RoW
Pexidartinib, TURALIO™️, PLX3397
Daiichi Sankyo, Inc.
Tenosynovial Giant Cell Tumor
07/23
07/23

Download Options